The $24M private placement provides a cash runway but at massive dilution cost, layered on top of a $100M ATM and a 58.9M-share S-3 resale registration. The company has no active pipeline and is pivoting to preclinical neurotechnology — a high-risk, early-stage pivot. Expect continued selling pressure as the ATM is utilized and the S-3 resale shares hit the market. Monitor for any Nasdaq compliance issues given the cumulative dilution.
Price Chart
Executive Summary
Indaptus Therapeutics entered into a stock purchase agreement for a $24M private placement of 20,338,974 shares, priced at Nasdaq Minimum Price plus $0.015. This capital raise follows a recently filed $100M ATM offering and an S-3 resale registration, creating a dual-track dilution scenario for a company with no active clinical programs and a going-concern risk. The massive dilution (15.3% of outstanding shares from this placement alone, plus the ATM overhang) is the dominant signal, overwhelming any positive from the cash infusion.
Key Financial Metrics
Key Facts
- Indaptus entered a $24M private placement of 20,338,974 shares at Nasdaq Minimum Price + $0.015.
- The company has 133,242,324 shares outstanding; this placement represents ~15.3% dilution.
- Proceeds are for working capital, R&D, and early-stage research on a neurotechnology device for sleep conditions.
- This filing follows a $100M ATM offering (filed Aug 31, 2026) and an S-3 resale registration for 58.9M shares (filed Aug 17, 2026).
- The company has no active clinical programs, having discontinued its lead candidate Decoy20, and faces a going-concern risk.
- Purchasers will receive registration rights for resale, adding future selling pressure.
Financial Impact
~$24M gross proceeds from 20.3M new shares, representing ~15.3% dilution on 133.2M shares outstanding. Combined with the $100M ATM and 58.9M S-3 resale shares, total potential dilution exceeds 100% of current float.
Risk Factors
- Massive cumulative dilution from this placement, the $100M ATM, and the 58.9M-share S-3 resale registration
- No active clinical programs; discontinued lead candidate Decoy20
- Going-concern risk; company is evaluating strategic alternatives
- Pivot to preclinical neurotechnology device is high-risk and early-stage
- Potential Nasdaq listing compliance issues from excessive dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-042037 |
| Document: form8-k.htm | 0001493152-26-042037 |
| Document: 0001493152-26-042037-index-headers.html | 0001493152-26-042037 |
| Document: 0001493152-26-042037-index.html | 0001493152-26-042037 |
| Document: 0001493152-26-042037.txt | 0001493152-26-042037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $2.56 $3.93 | ▼ −53.52% | ▼ −52.89% | $2.33 (+8.98%) |
Sep 4, 2026 27d ago | 424B5 | $1.85 $3.64 | ▼ −96.76% | ▼ −97.88% | $2.33 (−25.95%) |
Sep 1, 2026 4w ago | 8-K | $1.13 $2.08 | ▼ −84.07% | ▼ −83.99% | $2.33 (−106.19%) |
Aug 26, 2026 5w ago | EFFECT | $1.14 $1.17 | ▼ −2.63% | ▼ −2.75% | $2.33 (−104.39%) |
Aug 17, 2026 6w ago | S-3 | $0.9361 $1.10 | ▼ −16.97% | ▼ −17.18% | $2.33 (−148.91%) |
Aug 13, 2026 7w ago | 8-K | $1.06 $1.38 | ▲ +30.19% | ▲ +32.15% | $2.33 (+119.81%) |
Jul 20, 2026 10w ago | EFFECT | $2.46 $2.61 | ▼ −6.10% | ▼ −6.52% | $2.33 (+5.28%) |
Jun 26, 2026 13w ago | S-3 | $3.06 $2.85 | ▲ +6.86% | ▲ +8.25% | $2.33 (+23.86%) |
Jun 24, 2026 14w ago | 8-K | $3.26 $2.94 | ▲ +9.82% | ▲ +11.38% | $2.33 (+28.53%) |
May 15, 2026 20w ago | 8-K | $1.59 $1.22 | ▲ +23.27% | ▲ +24.23% | $2.33 (−46.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access